Skip to content
GLP-1 Decoder

Ozempic for Binge Eating: Evidence, Eligibility, Coverage

Ozempic is not FDA approved for binge eating. It is approved for type 2 diabetes, heart risk and kidney disease in type 2 diabetes. Some doctors prescribe it when one of those uses also applies. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.

Active ingredient
semaglutide
How it is taken
weekly injection
Approved for
Type 2 diabetes, heart risk and kidney disease in type 2 diabetes
Best result (STEP 1)
14.9% weight loss

A quick overview of Ozempic

Time in the body
100%50%25%0%07 d14 d21 d28 d35 d50%25%12.5%time after the dose

Its half-life is about 1 week: after 7 d, half is gone, and after five half-lives (35 d), about 3% remains

Weight loss in the main trial
Ozempic (SUSTAIN 1)4.7 kgPlacebo1.2 kg

Over 30 weeks, SUSTAIN 1 found 4.7 kg lost in type 2 diabetes, against 1.2 kg with placebo

Cost over time
202520262027$1,027.51$0List priceSelf-pay

Monthly prices in US dollars include the list price and self-pay offers, with each figure taken from the maker's price page

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Who qualifies?

Ozempic: who qualifies
Who sets the ruleWho qualifies
FDA labelWhen used with diet and exercise, this medicine lowers blood sugar in adults with Type 2 diabetes
FDA labelFor adults who have heart disease along with Type 2 diabetes, it lowers the risk of heart attack, stroke, and heart-related death
FDA labelIt lowers the risk of heart-related death, kidney failure, and worsening kidney disease in adults with Type 2 diabetes who have chronic kidney disease
Typical commercial plan (Aetna policy)BMI 30 or higher
Typical commercial plan (Aetna policy)BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)first comes a 6-month diet and activity program

Sources: FDA label (DailyMed), aetna.com.

Trial findings on binge eating

Not one of these trials enrolled people with binge eating alone. Everyone in the studies was an adult with obesity or overweight, and no participant had diabetes.

Trials using the same ingredient (semaglutide)
TrialMedicineWho took partLengthPeopleMain resultComparison
STEP 1 WegovyAdults with obesity or overweight, without diabetes68 weeks1,96114.9% weight loss2.4% on placebo
OASIS 4 WegovyAdults with obesity or overweight, without diabetes64 weeks30713.6% weight loss2.4% on placebo

Trial source: STEP 1 (FDA label (DailyMed)).

For binge eating, what changes?

Label highlights for binge eating with Ozempic
What changesWhat the label says
Severe Gastrointestinal Adverse ReactionsStomach and gut side effects are common and can be severe Not recommended for people with severe gastroparesis.

According to the FDA labels: FDA DailyMed label.

Source for the label warning: FDA label (DailyMed).

Coverage for binge eating

When a GLP-1 is used only for weight loss, Medicare Part D does not pay for it.

Where Medicaid covers weight-loss GLP-1s, prior authorization is the usual rule.

Sources: humana.com, KFF.

Other options for binge eating

GLP-1 medicines and binge eating
MedicineFor binge eatingHow it is takenTrial result
OzempicNot a listed useweekly injectionNot listed
WegovyNot a listed useweekly injection or daily tablet14.9% weight loss
RybelsusNot a listed usedaily tabletNot listed
MounjaroNot a listed useweekly injectionNot listed
ZepboundNot a listed useweekly injection20.9% weight loss
FoundayoNot a listed usedaily tablet11.1% weight loss
TrulicityNot a listed useweekly injectionNot listed
SaxendaNot a listed usedaily injection7.4% weight loss
VictozaNot a listed usedaily injectionNot listed
ByettaNot a listed usetwice-daily injectionNot listed

Sources: FDA label (DailyMed).

Questions for your prescriber

Read the full Ozempic prescribing information on DailyMed.